I am trying to understand the disparity in dosage of the beta-cell cytotoxic agent streptozotocin, specifically for the induction of type 2 diabetes, between rat models and mouse models. We are attempting to induce t2d in mice, while most of the studies online document rats as their model of choice. The goal is sustained hyperglycaemia, while accelerating the diabetic condition and concurrently preventing animal death by cytotoxic effects, at least for a 20 week period (although a longer period would be preferred). Please help.